ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBPBiotechnology
+$0.44 today
- Market cap
- $563.78M
- Beta
- 1.42
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$3.22
Volume 2.70M
Average 0.50M
AVBP Other Working Capital
Cash effect of changes in other operating assets and liabilities.
ArriVent BioPharma, Inc. Common StockNASDAQ: AVBP
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital declines year over year
Q1 FY2026 other working capital of $6.31M (cash outflow) fell 2.6% year over year, ahead of the -304.7% change in trailing-twelve-month other working capital. Over 3 fiscal years it compounded at -15.9% a year.
Context
- Other working capital increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -2.6% holds above the trailing-twelve-month pace of -304.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (5.92M) USD
- Year-over-year change
- -175.6%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (5.92M) | -175.6% |
| FY2024 | 2024-12-31 | 7.82M | -30.3% |
| FY2023 | 2023-12-31 | 11.22M | +212.7% |
| FY2022 | 2022-12-31 | (9.95M) | -135.0% |
| FY2021 | 2021-12-31 | (4.23M) | — |
Other Working Capital vs competitors
How AVBP compares with its peers on the latest reported figures
- AVBP's LTM Mar 2026 other working capital of $5.75M is the 8th largest of the 11 companies compared; the peer median is $5.45M.
- Its year-over-year change of -304.7% is the lowest of 11, against a peer median of +94.1%.
- Over three fiscal years its annual growth of -15.9% compares with a peer median of -22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $45.77M | +154.4% | +13.0% | 1.9% | |
| LTM Jun 2025 | $40.15M | -258.2% | — | 6.7% | |
| LTM Jun 2026 | $22.18M | +273.1% | -34.2% | 13.1% | |
| LTM Sep 2026 | $12.05M | +385.4% | — | — | |
| LTM Jun 2026 | $10.82M | +145.6% | — | 2.4% | |
| LTM Mar 2026 | $7.39M | +153.3% | — | 3.3% | |
| LTM Mar 2026 | $6.86M | +42.5% | -11.6% | — | |
| LTM Mar 2026 | $5.75M | -304.7% | -15.9% | — | |
| LTM Mar 2026 | $3.51M | -63.6% | -73.5% | 1.6% | |
| LTM Mar 2026 | $999K | -132.2% | -34.7% | — | |
| LTM Mar 2026 | $526K | -126.6% | +20.2% | — | |
| Peer median (excluding AVBP) | $5.45M | +94.1% | -22.9% | 2.8% | |
Competitors are the stored peer set for AVBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (51.61M) | (36.91M) | (69.33M) | (80.49M) | (166.31M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | (3.03M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 66.67K | 424K | 895K | 3.21M | 12.52M |
| Change in Working Capital | (3.94M) | (7.15M) | 12.6M | 7.07M | (3.77M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 293K | 2.8M | 1.38M | (751K) | 2.14M |
| Other Working Capital | (4.23M) | (9.95M) | 11.22M | 7.82M | (5.92M) |
| Other Non-Cash Items | 42.96M | 0 | 0 | 0 | 0 |
| Operating Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (25M) | (194.16M) | (272.93M) |
| Sales of Investments | 0 | 0 | 25M | 1.7M | 201.71M |
| Other Investing Activities | (40M) | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (40M) | 0 | 0 | (192.47M) | (71.23M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.87M | 2K | 354K | 185.95M | 202.63M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 15K | (2.06M) | 631K | (70K) |
| Financing Cash Flow | 89.87M | 169.72M | 42.86M | 186.58M | 203.06M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 37.28M | 126.09M | (12.98M) | (76.1M) | (28.75M) |
| Free Cash Flow | (12.59M) | (43.63M) | (55.84M) | (70.21M) | (160.59M) |
ArriVent BioPharma, Inc. Common Stock
NASDAQ:AVBP
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.